Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Mov Disord ; 23(4): 596-9, 2008 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-18175346

RESUMEN

Idiopathic rapid-eye-movement (REM) sleep behavior disorder (iRBD) has been suggested to be a risk factor for subsequent development of neurodegenerative disorders, especially Parkinson's disease (PD) and other alpha-synucleinopathies. At present, it is not possible to predict whether or not an iRBD patient will eventually develop PD. Here, we report 5 iRBD patients who underwent a test battery comprising a neurological examination (including UPDRS rating), mini mental state examination testing, transcranial sonography, olfactory function testing, and presynaptic dopamine transporter imaging with FP-CIT-SPECT. Our preliminary data show the diverse pattern of individual combinations of pathological findings when a multimodal assessment approach is applied in this patient group. Large-size longitudinal studies in iRBD patients are required to evaluate the usefulness of diagnostic tests to identify the subgroup of iRBD patients that is prone to develop PD.


Asunto(s)
Trastornos del Olfato/epidemiología , Trastornos del Olfato/fisiopatología , Trastorno de la Conducta del Sueño REM/diagnóstico , Trastorno de la Conducta del Sueño REM/epidemiología , Radiofármacos , Tomografía Computarizada de Emisión de Fotón Único , Tropanos , Ultrasonografía Doppler Transcraneal/métodos , Anciano , Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Trastornos del Olfato/diagnóstico , Índice de Severidad de la Enfermedad , Sustancia Negra/diagnóstico por imagen , Sustancia Negra/metabolismo , Sustancia Negra/fisiopatología
2.
PLoS One ; 11(3): e0151316, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26991494

RESUMEN

This prospective, randomized, placebo-controlled, double-blinded phase I clinical trial investigates safety and efficacy of botulinum toxin (BoNT) to preserve gland function after radiotherapy in patients with head and neck cancer. Twelve patients with advanced head and neck cancer were injected with BoNT into the submandibular glands prior to primary radiochemotherapy. Six patients received BoNT/A and 6 patients BoNT/A and B, half of each subgroup into their left and the other half into their right gland. As an internal control, sodium chloride was injected into the respective contralateral gland (placebo). For the evaluation of the salivary gland function, technetium pertechnetate salivary gland scintigraphy was performed before and after the end of radiotherapy. BoNT/A and B were well tolerated. Analysis of the scintigraphic data revealed no statistically significant difference between BoNT and placebo regarding the scintigraphic uptake difference (pBoNT/A = 0.84 and pBoNT/A-B = 0.56 for BoNT/A vs. placebo and BoNT/A-B vs. placebo, respectively). We also found no significant difference in treatment between BoNT and placebo in terms of salivary excretion fraction (pBoNT/A = 0.44; pBoNT/A-B = 0.44). This study demonstrates that BoNT can be safely combined with radiochemotherapy. Dosing and timing of BoNT injection should be further investigated for efficacy analysis. Trial Registration German Registry for Clinical Trails DRKS00004595.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Carcinoma de Células Escamosas/radioterapia , Neoplasias de Cabeza y Cuello/radioterapia , Radioterapia/efectos adversos , Glándulas Salivales/efectos de los fármacos , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/efectos adversos , Carcinoma de Células Escamosas/tratamiento farmacológico , Quimioradioterapia/efectos adversos , Método Doble Ciego , Femenino , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Cintigrafía/métodos , Glándulas Salivales/fisiología , Glándulas Salivales/efectos de la radiación , Carcinoma de Células Escamosas de Cabeza y Cuello , Resultado del Tratamiento
3.
Epilepsy Res ; 62(1): 89-93, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15519135

RESUMEN

Ictal functional transcranial Doppler sonography (I-fTCD) was used to lateralize the ictal onset zone in the presurgical evaluation of two patients with temporal lobe epilepsy. In one patient, I-fTCD and ictal SPECT were performed simultaneously during EEG-monitoring. In both patients, results were concordant with the ictal SPECT findings, PET and semiology. I-fTCD seems to be an interesting new method to non-invasively lateralize the seizure onset zone with high temporal resolution. I-fTCD and SPECT may give complementary information to lateralize the seizure onset zone.


Asunto(s)
Epilepsia del Lóbulo Temporal/diagnóstico por imagen , Convulsiones/diagnóstico por imagen , Adulto , Electroencefalografía , Epilepsia del Lóbulo Temporal/cirugía , Femenino , Lateralidad Funcional/fisiología , Humanos , Arteria Cerebral Media/diagnóstico por imagen , Procedimientos Neuroquirúrgicos , Convulsiones/cirugía , Tomografía Computarizada de Emisión de Fotón Único , Ultrasonografía Doppler Transcraneal
4.
PLoS One ; 9(7): e102397, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25028935

RESUMEN

With the aim to develop beneficial tracers for cerebral tumors, we tested two novel 5-iodo-2'-deoxyuridine (IUdR) derivatives, diesterified at the deoxyribose residue. The substances were designed to enhance the uptake into brain tumor tissue and to prolong the availability in the organism. We synthesized carrier added 5-[125I]iodo-3',5'-di-O-acetyl-2'-deoxyuridine (Ac2[125I]IUdR), 5-[125I]iodo-3',5'-di-O-pivaloyl-2'-deoxyuridine (Piv2[125I]IUdR) and their respective precursor molecules for the first time. HPLC was used for purification and to determine the specific activities. The iodonucleoside tracer were tested for their stability against human thymidine phosphorylase. DNA integration of each tracer was determined in 2 glioma cell lines (Gl261, CRL2397) and in PC12 cells in vitro. In mice, we measured the relative biodistribution and the tracer uptake in grafted brain tumors. Ac2[125I]IUdR, Piv2[125I]IUdR and [125I]IUdR (control) were prepared with labeling yields of 31-47% and radiochemical purities of >99% (HPLC). Both diesterified iodonucleoside tracers showed a nearly 100% resistance against degradation by thymidine phosphorylase. Ac2[125I]IUdR and Piv2[125I]IUdR were specifically integrated into the DNA of all tested tumor cell lines but to a less extend than the control [125I]IUdR. In mice, 24 h after i.p. injection, brain radioactivity uptakes were in the following order Piv2[125I]IUdR>Ac2[125I]IUdR>[125I]IUdR. For Ac2[125I]IUdR we detected lower amounts of radioactivities in the thyroid and stomach, suggesting a higher stability toward deiodination. In mice bearing unilateral graft-induced brain tumors, the uptake ratios of tumor-bearing to healthy hemisphere were 51, 68 and 6 for [125I]IUdR, Ac2[125I]IUdR and Piv2[125I]IUdR, respectively. Esterifications of both deoxyribosyl hydroxyl groups of the tumor tracer IUdR lead to advantageous properties regarding uptake into brain tumor tissue and metabolic stability.


Asunto(s)
Neoplasias Encefálicas/diagnóstico , Idoxuridina/química , Radioisótopos de Yodo/química , Trazadores Radiactivos , Animales , Línea Celular Tumoral , Cromatografía Líquida de Alta Presión , Esterificación , Humanos , Idoxuridina/farmacocinética , Radioisótopos de Yodo/farmacocinética , Ratones , Timidina Fosforilasa/metabolismo
5.
In Vivo ; 24(5): 681-5, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20952733

RESUMEN

BACKGROUND: Salivary gland dysfunction with xerostomia is a major clinical problem without a causal therapy in most cases. The development of an animal model for scintigraphic assessment of salivary gland function has great clinical relevance for the investigation of promising new diagnostic and therapeutic strategies for chronic salivary gland diseases. This study reports the first experiences with scintigraphic analyses of salivary gland function in a rat model. MATERIALS AND METHODS: Anatomical and scintigraphic studies were performed for topographic differentiation of major salivary glands of Wistar rats. (99m)technetium pertechnetate salivary gland scanning was performed, appropriate regions of interest were determined and the gland-to-background ratio was examined for the evaluation of salivary gland function. RESULTS: The quantitative analysis of salivary gland scintigraphy revealed a reliable comparison of major salivary glands on both sides with the gland-to-background ratio ranging from 1.26 to 1.94 with an average of 1.51. CONCLUSION: This model seems to be appropriate for functional studies in an experimental setting.


Asunto(s)
Modelos Animales de Enfermedad , Cintigrafía/métodos , Ratas Wistar , Glándulas Salivales/diagnóstico por imagen , Xerostomía/diagnóstico por imagen , Animales , Enfermedad Crónica , Masculino , Glándula Parótida/diagnóstico por imagen , Radiofármacos , Ratas , Pertecnetato de Sodio Tc 99m , Glándula Sublingual/diagnóstico por imagen , Glándula Submandibular/diagnóstico por imagen
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA